Listen in to hear more about the future of pharmaceutical pricing, focusing on the three key issues of affordability, evidence and value attribution.
Listen in to hear tips for pharma manufacturers as they develop their market access strategies and prepare to launch physician-administered therapies.
Are Drug Prices Too High? Should QALYs Be Used to Measure a Drug's Value? And Should a Government Entity Be Making Price and Value Determinations? A Conversation with Dan Ollendorf.Dan Ollendorf, Ph.D., M.P.H.,of the Center for the Evaluation of Value and Risk in Health at Tufts University Medical Center, is co-author of a new book, The Right Price, A Value-Based Prescription for Drug Costs.
Steven D. Pearson, M.D., M.Sc., founder and president of ICER addresses if pricing of PCSK9 inhibitors put ICER on the map.
Can price affect access?
Discussion on high-priced drugs and whether the prices are sustainable in the long run.